Core Viewpoint - The article discusses the role of mast cell receptor Mrgprb2 in mediating post-stroke brain inflammation, highlighting its potential as a therapeutic target to improve neurological outcomes after stroke [4][10]. Group 1: Research Findings - The study published in Cell reveals that the mast cell-specific receptor Mrgprb2 mediates brain inflammation after stroke through a dural-brain signaling axis [5][10]. - Inhibition of Mrgprb2 reduces post-stroke brain inflammation in mice, leading to improved neurological function and increased survival rates [5][10]. - Mrgprb2 acts as a key "gatekeeper" for the migration of immune cells from the skull bone marrow to the brain [13][14]. Group 2: Mechanisms of Action - Mrgprb2 activation leads to degranulation of mast cells in the meninges, releasing immune mediators that recruit neutrophils to the dura mater and promote their migration into brain tissue [8][14]. - The study indicates that mast cell proteases can cleave semaphorin proteins, facilitating neutrophil infiltration into the brain [14]. Group 3: Related Research - Another study published on the same day in Cell by Jonathan Kipnis's team discusses how mast cells regulate the brain-dura interface and cerebrospinal fluid (CSF) dynamics [15][19]. - The findings suggest that mast cells are crucial regulators of CSF flow and meningeal immunity, with potential implications for enhancing CNS clearance and defense mechanisms against infections [19].

证券分析师：陈曦炳 0755-81982939 chenxibing@guosen.com.cn S0980521120001 证券分析师：彭思宇 0755-81982723 pengsiyu@guosen.com.cn S0980521060003 请务必阅读正文之后的免责声明及其项下所有内容 摘要 证券研究报告 | 2025年06月17日 创新药盘点系列报告（22） ——IBD治疗领域存在未满足的需求，关注新靶点、新机制 行业研究 · 行业专题 医药生物 · 生物制品 投资评级：优于大市（维持评级） 证券分析师：马千里 010-88005445 maqianli@guosen.com.cn S0980521070001 请务必阅读正文之后的免责声明及其项下所有内容 2 ◼ IBD治疗领域存在未满足的需求。美国及欧洲5国适用于生物制剂治疗的中重度患者人群总计~230万人（CD/UC分别~100/~130万人）， 患者人群体量对标AD/特应性皮炎（~280万人）及PsO/银屑病（~240万人）；IBD具有复发-缓解交替特点，患者常出现黏膜损伤、肠 腔狭窄、瘘管、肛周病变等并发症，最终仍有相当比例患者需接受手术 ...